These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21241278)

  • 1. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
    Hunsucker SA; Magarotto V; Kuhn DJ; Kornblau SM; Wang M; Weber DM; Thomas SK; Shah JJ; Voorhees PM; Xie H; Cornfeld M; Nemeth JA; Orlowski RZ
    Br J Haematol; 2011 Mar; 152(5):579-92. PubMed ID: 21241278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
    Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
    Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
    Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Bashir Q; Qazilbash MH; Andersson BS
    Exp Hematol; 2020 Jan; 81():32-41. PubMed ID: 31954171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
    Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK
    Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
    Voorhees PM; Chen Q; Small GW; Kuhn DJ; Hunsucker SA; Nemeth JA; Orlowski RZ
    Br J Haematol; 2009 May; 145(4):481-90. PubMed ID: 19344406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
    Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
    Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
    Viktorsson K; Shah CH; Juntti T; Hååg P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullén A
    Mol Oncol; 2016 May; 10(5):719-34. PubMed ID: 26827254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
    Gupta D; Podar K; Tai YT; Lin B; Hideshima T; Akiyama M; LeBlanc R; Catley L; Mitsiades N; Mitsiades C; Chauhan D; Munshi NC; Anderson KC
    Exp Hematol; 2002 Jul; 30(7):711-20. PubMed ID: 12135668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.
    Shi Y; Hsu JH; Hu L; Gera J; Lichtenstein A
    J Biol Chem; 2002 May; 277(18):15712-20. PubMed ID: 11872747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
    Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
    Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
    Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
    Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
    Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.